Damage Control for Big Pharma
Stricter regulation, a dearth of new blockbuster drugs, increased pressure to lower prices and more intense generic competition hammered the pharmaceutical industry in 2008, but its stocks still weathered the market collapse better than many other sectors.
The industry's ills predate the financial crisis but are being exacerbated as the recession pushes poor patients to delay refills, trade down to generics and split pills.
Source: Associated Press















